This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Ionis Pharmaceuticals's Median PS Value or its related term are showing as below:
IONS'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.42 Med: 0.78 Max: 1.78
Current: 0.86
During the past 13 years, the highest Price to Median PS Value of Ionis Pharmaceuticals was 1.78. The lowest was 0.42. And the median was 0.78.
IONS's Price-to-Median-PS-Value is ranked worse than 62.4% of 250
companies
in the Biotechnology industry
Industry Median: 0.71
vs IONS: 0.86
Ionis Pharmaceuticals Median PS Value Historical Data
The historical data trend for Ionis Pharmaceuticals's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ionis Pharmaceuticals's Median PS Value
For the Biotechnology subindustry, Ionis Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 10.3144.
Ionis Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.708.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ionis Pharmaceuticals (NAS:IONS) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Ionis Pharmaceuticals's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
42.00
/
48.56
=
0.86
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ionis Pharmaceuticals Median PS Value Related Terms
Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IONS has been successfully added to your 